---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-000180"
form_type: "8-K"
ticker: "FNCHQ"
cik: "0001733257"
company_name: "Finch Therapeutics Group, Inc."
filed_at: "2022-01-10T23:59:59+00:00"
generated_at: "2026-06-27T19:31:14.395554+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "medium"
source: SEC EDGAR
---

# Finch Therapeutics reports preliminary cash of $133.5M as of Dec 31, 2021

## Summary
- Preliminary cash and cash equivalents of approximately $133.5M as of Dec 31, 2021.
- CEO Mark Smith to present at J.P. Morgan Healthcare Conference on Jan 13, 2022.
- Updated corporate presentation posted on company website for investor meetings.
- Year-end audit ongoing; final cash balance may differ from preliminary estimate.

## SEC filing metadata
- accession: 0000950170-22-000180
- form_type: 8-K
- ticker: FNCHQ
- cik: 0001733257
- company_name: Finch Therapeutics Group, Inc.
- filed_at: 2022-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: medium
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1733257/000095017022000180/0000950170-22-000180-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1733257/000095017022000180/fnch-20220110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-000180
- JSON: https://secwatch.observer/filing/0000950170-22-000180.json
- Plain text: https://secwatch.observer/filing/0000950170-22-000180.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.